Drugs / Histrelin
Histrelin
also known as
histrelin acetate · Histrelina · Histreline · ORF 17070 · ORF 17070RWJ 17070 · RWJ 17070 · Supprelin · Supprelin la · +1 more
Other / unclassified targets GNRHR via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SUPPRELIN | — | 1991-12-24 | fda.gov ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT00779103 | Sep 2004 → Aug 2011 | central precocious puberty | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT01394263 | May 2000 → Dec 2001 | prostate adenocarcinoma | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 3 | NCT01697384 | Apr 2000 → Aug 2003 | prostate adenocarcinoma | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT06378866 Comparator | Jun 2024 → Feb 2031 expected | castration-resistant prostate carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT02278185 Comparator | Nov 2015 → Apr 2019 | prostate adenocarcinoma | University of Colorado, Denver | Completed | Missed primary |
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 overdue | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 3 | NCT05050084 Background | Dec 2021 → Nov 2026 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513717 Background | Jan 2021 → Dec 2033 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03678025 Background | Sep 2018 → Apr 2033 expected | prostate adenocarcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-04-04 | Orion Corporation, Orion Pharma | Orion receives European rights from Indevus for Vantas®, for prostate cancer orionpharma.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Histrelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06378866 ↗ |
| Known as | histrelin acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01697384 ↗ |
| Known as | Histrelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Known as | Histreline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Known as | ORF 17070 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Known as | ORF 17070RWJ 17070 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Known as | RWJ 17070 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Known as | Supprelin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Known as | Supprelin la | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Known as | Vantas | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201255 ↗ |
| Action | Activate | “Gonadotropin-releasing hormone receptor agonist” CHEMBL1201255 ↗ |
| Action | Inhibit | “Long-term histrelin implant therapy provided sustained gonadotropin suppression safely and effectively” PMID 25803268 ↗ Mar 2015 |
| Modality | Other / unclassified | “GnRH analog (GnRHa) therapy” PMID 25803268 ↗ Mar 2015 |
| Route | Subcutaneous | “histrelin subcutaneous 50 mg implant” NCT00779103 ↗ |
| Target | GNRHR | “Gonadotropin-releasing hormone receptor agonist” CHEMBL1201255 ↗ |